ASSESSING METASTASIS/RELAPSE IN SENTINEL LYMPH NODE DISSECTION MELANOMA PATIENTS

该方案项目的重点是评估 高危AJCC II期患者的前哨淋巴结清扫术（SLND） 参加了多中心试验（MECHANISM）。精准识别和 前哨淋巴结的分析可以改善疾病分期， 进一步治疗。然而，需要更好的方法来检测 转移性疾病和早期患者复发的预测。的 SLND患者的黑色素瘤病灶、前哨淋巴结和血液 是评估新分子方法学的宝贵资源。 该项目将侧重于开发新的分子方法，以改善 检测血液和前哨淋巴结中的转移性疾病。 开发用于RT-PCR和自动化Souther印迹分析的黑色素瘤标志物 将用于评估血液和前哨淋巴结。我们将评估 这些分子标记物用于检测 亚临床疾病和使用血液样本预测复发 SLND患者。我们还将使用黑色素瘤标志物RT-PCR检测 前哨淋巴结冷冻石蜡标本选择中的转移 结主要目的是提高微转移的检测 前哨淋巴结疾病。主要目标是改善 前哨淋巴结微转移疾病的检测和复发 血液中的亚临床疾病，以确定其潜力 在疾病分期和预后中的临床病理学效用。了一种方法 用来检测血清中的肿瘤特异性DNA标记这些 将使用前瞻性方法评估标记物作为肿瘤进展指标， 和存档血清目的是确定高血压患者， 发展为侵袭性疾病的可能性。马格德堡档案馆和 前瞻性标本沿着其临床随访提供了一个独特的 用于验证和确定这些新分子的临床效用的资源 方法。

The Program Project's focus os on the assessment of the efficacy of sentinel lymph node dissection (SLND) in high-risk AJCC Stage II patients enrolled in the multi-center trial (MSLT). Accurate identification and analysis of the sentinel node can improve disease staging and guide further treatment. However, better methods are needed for the detection of metastatic disease and prediction of relapse in early-stage patients. The melanoma lesion, sentinel lymph node and blood of patients undergoing SLND are valuable resource for assessing new molecular methodologies. The project will focus on developing new molecular approaches to improve detection of metastatic disease in blood and sentinel lymph nodes. Melanoma markers developed for RT-PCR and automated Souther blot analysis will be used to evaluate blood and sentinel lymph nodes. We will assess the clinical utility of these molecular markers for detection of subclinical disease and prediction of relapse using blood specimens from SLND patients. We will also use melanoma marker RT-PCR to detect metastasis in frozen and archival paraffin selection of sentinel lymph nodes. The main objective will be to improve detection of micrometastic disease in sentinel lymph nodes. The main objective will be to improve detection of micrometastatic disease in sentinel lymph nodes and recurrent subclinical disease in blood to determine their potential clinicopathological utility in disease staging and prognosis. A method has been developed to asses tumor- specific DNA markers in serum. These markers will be assessed as tumor progression indicators using prospective and archival serum. The objective will be to identify patients with high potential for developing aggressive disease. The MSLT archival and prospective specimens along with their clinical follow up provide a unique resource to validate and determine clinical utility of these new molecular approaches.